for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hologic, Inc.

HOLX.O

Latest Trade

50.18USD

Change

0.68(+1.37%)

Volume

2,138,566

Today's Range

49.22

 - 

50.25

52 Week Range

37.48

 - 

52.19

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
49.50
Open
49.61
Volume
2,138,566
3M AVG Volume
47.30
Today's High
50.25
Today's Low
49.22
52 Week High
52.19
52 Week Low
37.48
Shares Out (MIL)
272.13
Market Cap (MIL)
13,231.65
Forward P/E
18.82
Dividend (Yield %)
--

Next Event

Hologic Inc at Evercore HealthCONx Conference

Latest Developments

More

Hologic To Sell Cynosure Medical Aesthetics Business To Clayton, Dubilier & Rice

Hologic Announces FDA Approval Of 3Dquorum Imaging Technology, Powered By Genius AI

Hologic Reports Q4 Non-GAAP Earnings Per Share Of $0.65

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hologic, Inc.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Industry

Medical Equipment & Supplies

Contact Info

250 Campus Dr

+1.508.2632900

https://www.hologic.com/

Executive Leadership

Stephen P. MacMillan

Chairman of the Board, President, Chief Executive Officer

Karleen Marie Oberton

Chief Financial Officer

Peter J. Valenti

Division President - Breast and Skeletal Health

Allison P. Bebo

Senior Vice President - Human Resources

John M. Griffin

General Counsel

Key Stats

2.28 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

3.1K

2018

3.2K

2019

3.4K

2020(E)

3.5K
EPS (USD)

2017

2.030

2018

2.230

2019

2.430

2020(E)

2.630
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.93
Price To Book (MRQ)
5.91
Price To Cash Flow (TTM)
30.92
Total Debt To Equity (MRQ)
134.04
LT Debt To Equity (MRQ)
122.14
Return on Investment (TTM)
-0.62
Return on Equity (TTM)
-0.51

Latest News

Latest News

Hologic loses bid to dismiss bioMerieux's HIV test patent case

Diagnostic testing company bioMerieux SA can move forward with a lawsuit alleging that HIV testing kits manufactured by rival Hologic Inc infringe two of its patents, a federal judge in Delaware has ruled.

Hologic wins $4.8 million from Minerva Surgical in patent trial

A federal jury on Friday awarded medical device maker Hologic Inc $4.8 million in its patent infringement lawsuit against rival Minerva Surgical Inc.

BRIEF-Hologic Receives Health Canada Authorization To Market Sculpsure Laser

* HOLOGIC RECEIVES HEALTH CANADA AUTHORIZATION TO MARKET SCULPSURE® LASER FOR NON-INVASIVE BODY CONTOURING (LIPOLYSIS) OF THE BACK, INNER AND OUTER THIGHS, AND UNDER THE CHIN Source text for Eikon: Further company coverage:

BRIEF-Hologic Q2 GAAP Loss Per Share $2.46

* HOLOGIC ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL 2018

BRIEF-FDA Approval Of Thinprep Integrated Imager Expands Automated Imaging For Pap Testing To More Labs

* FDA APPROVAL OF THINPREP® INTEGRATED IMAGER EXPANDS AUTOMATED IMAGING FOR PAP TESTING TO MORE LABS

BRIEF-Enzo Biochem Says Patent Trial And Appeal Board Has Denied A Petition Filed By Hologic For Inter Partes Review

* ENZO BIOCHEM INC - PATENT TRIAL AND APPEAL BOARD HAS DENIED A PETITION FILED BY HOLOGIC FOR INTER PARTES REVIEW Source text for Eikon: Further company coverage:

BRIEF-FDA Approves New Innovations On Hologic's 3Dimensions™ Mammography System

* FDA APPROVES NEW INNOVATIONS ON HOLOGIC'S 3DIMENSIONS™ MAMMOGRAPHY SYSTEM, THE FASTEST, HIGHEST RESOLUTION BREAST TOMOSYNTHESIS SYSTEM EVER(1)

Appeals court hands win to Smith & Nephew in Hologic patent case

A federal appeals court on Wednesday upheld the validity of a surgical tool patent over which medical device maker Smith & Nephew PLC won a $4 million verdict against rival Hologic Inc.

BRIEF-Koninklijke Philips And Hologic Announce Global Partnership Agreement

* PHILIPS AND HOLOGIC ANNOUNCE GLOBAL PARTNERSHIP AGREEMENT TO PROVIDE INTEGRATED IMAGING SOLUTIONS FOR WOMEN'S HEALTH

BRIEF-Hologic Reports Q1 GAAP Earnings Per Share $1.45

* HOLOGIC ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL 2018

BRIEF-Hologic - CEO's 2017 Total Compensation Was $11.2 Million Vs $10.8 Million

* HOLOGIC INC - CEO STEPHEN P. MACMILLAN'S 2017 TOTAL COMPENSATION WAS $11.2 MILLION VERSUS $10.8 MILLION - SEC FILING Source text: (http://bit.ly/2nhdmKL) Further company coverage:

BRIEF-Third Respiratory Assay now FDA cleared on Hologic's new Panther Fusion system

* THIRD RESPIRATORY ASSAY NOW FDA CLEARED ON HOLOGIC'S NEW PANTHER FUSION® SYSTEM

BRIEF-HOLOGIC RECEIVES FDA 510(K) CLEARANCE OF QUANTRA 2.2 BREAST DENSITY ASSESSMENT SOFTWARE

* HOLOGIC RECEIVES FDA 510(K) CLEARANCE OF QUANTRA 2.2 BREAST DENSITY ASSESSMENT SOFTWARE

BRIEF-Hologic announces upcoming put option

* Hologic announces upcoming put option and notice of redemption of 2.00% convertible senior notes due 2043 Source text for Eikon: Further company coverage:

BRIEF-Hologic announces Q4 GAAP earnings per share $0.29

* Hologic announces financial results for fourth quarter of fiscal 2017

BRIEF-Hologic - ‍received 510(k) clearance from FDA for Panther Fusion Paraflu assay​

* Hologic Inc - received 510(k) clearance from FDA for Panther Fusion Paraflu assay Source text for Eikon: Further company coverage:

BRIEF-Hologic prices offering of $350 mln 4.375 pct senior notes due 2025

* Hologic announces pricing of offering of $350 million aggregate principal amount of 4.375% senior notes due 2025

BRIEF-Hologic announces offering of $350 mln of senior notes due 2025

* Hologic announces offering of $350 million of senior notes due 2025

BRIEF-Hologic enters into amended and restated five-year secured credit agreement

* Hologic enters into amended and restated five-year secured credit agreement

BRIEF-Hologic receives FDA 510(k) clearance to market SculpSure

* Hologic receives FDA 510(k) clearance to market SculpSure for non-invasive body contouring (lipolysis) of the submental area (under the chin)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up